The ideal versus real world Pharmaceutical companies and the FDA have an obligation to make patients and prescribers aware of the potential risks of medications
Also, the lack of a comprehensive analysis of muscle mass across multiple muscle groups and tissues may have limited our ability to fully assess the impact of GLP-1 analogs on muscle health
174 Currently, Eli Lilly has initiated a Phase III development program to further investigate the efficacy and safety of orforglipron in treating obesity, overweight, and T2DM
They found that carnitine administration was associated with a significant reduction in BMI, and waist and hip circumferences compared to placebo
CGRP was decreased by 6275% in rats with capsaicin treatment, while TH was not different between the rats with and without capsaicin treatment
The most common reasons include: Gastrointestinal side effects such as nausea, vomiting and diarrhea which are the single most frequently documented reason for stopping in large health system datasets High out of pocket cost and lack of insurance coverage particularly in individuals without diabetes Medication unavailability or pharmacy supply shortages which peaked in 2023early 2024 Perceived completion of therapy once target weight is reached or weight loss plateaus Concerns about long term safety or treatment burden of injections Many cohorts show substantial discontinuation by 3 months, with further losses by 6-9 months
